LIXTE Biotechnology Advances PP2A Inhibitor LB-100 to Enhance Cancer Therapy Response
LIXTE Biotechnology is developing experimental compound LB-100 to inhibit PP2A and boost tumor sensitivity to chemotherapy, radiation and immunotherapy. The strategy aims to enhance immune recognition and treatment efficacy by targeting PP2A alongside existing cancer therapies.
1. Experimental Compound LB-100 Targets PP2A
LIXTE Biotechnology is advancing its experimental molecule LB-100, designed to inhibit protein phosphatase 2A (PP2A) in tumor cells. By blocking PP2A activity, LB-100 may increase cancer cell vulnerability to DNA damage from chemotherapy and radiation.
2. Synergy with Immunotherapy and Chemotherapy
The PP2A inhibition approach is intended to complement immune checkpoint inhibitors and standard cytotoxic regimens, enhancing T-cell recognition and improving overall tumor response rates. LIXTE’s strategy focuses on integrating LB-100 with existing treatments to address cancers with limited immunotherapy responsiveness.